| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
Over the last 12 months, insiders at Protalix BioTherapeutics, Inc. have bought $0 and sold $0 worth of Protalix BioTherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Protalix BioTherapeutics, Inc. have bought $116,100 and sold $2.09M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 64,516 shares for transaction amount of $90,484 was made by Bashan Dror (PRESIDENT AND CEO) on 2023‑10‑19.
| 2023-10-19 | Bashan Dror | PRESIDENT AND CEO | 64,516 0.0878% | $1.40 | $90,484 | -17.12% | ||
| 2023-01-03 | Schwartz Aharon | director | 110,000 0.1979% | $1.42 | $155,815 | +30.66% | ||
| 2022-04-11 | Bashan Dror | President and CEO | 68,000 0.1528% | $1.50 | $102,000 | -19.15% | ||
| 2021-06-03 | Sale | Dexcel Pharma Technologies Ltd. | 10 percent owner | 857,506 1.9156% | $2.25 | $1.93M | -48.20% | |
| 2021-06-02 | Sale | Dexcel Pharma Technologies Ltd. | 10 percent owner | 61,211 0.1389% | $2.56 | $156,553 | -53.63% | |
| 2020-04-07 | Schwartz Aharon | director | 64,000 0.1994% | $2.43 | $155,264 | +53.33% | ||
| 2017-05-16 | Manor Moshe | President & CEO | 50,000 0.0383% | $0.81 | $40,500 | -20.48% | ||
| 2016-12-02 | Sale | Camber Capital Management LLC | 10 percent owner | 2.5M 2.5199% | $0.32 | $792,000 | +144.13% | |
| 2015-12-14 | Maimon Yossi | Vice President & CFO | 10,000 0.01% | $0.78 | $7,800 | -2.56% | ||
| 2015-10-19 | Camber Capital Management LLC | 10 percent owner | 4M 4.0937% | $1.00 | $4M | -18.37% | ||
| 2014-08-13 | Sale | Bronfeld Zeev | 4.4M 4.4447% | $2.47 | $10.87M | -21.67% | ||
| 2014-08-13 | Sale | Bio-Cell Ltd | 10 percent owner | 4.4M 4.4447% | $2.47 | $10.87M | -21.67% | |
| 2013-08-15 | Sale | Akirov Alfred | director | 2,330 0.0025% | $5.07 | $11,813 | -14.98% | |
| 2013-08-14 | Sale | Akirov Alfred | director | 110,000 0.1193% | $5.05 | $555,750 | -14.78% | |
| 2013-03-12 | Sale | Akirov Alfred | director | 10,000 0.0108% | $5.70 | $57,000 | -12.63% | |
| 2013-03-11 | Sale | Akirov Alfred | director | 18,300 0.0198% | $5.72 | $104,737 | -12.63% | |
| 2013-03-08 | Sale | Akirov Alfred | director | 16,898 0.0182% | $5.86 | $99,068 | -14.94% | |
| 2013-03-07 | Sale | Akirov Alfred | director | 8,435 0.0092% | $5.72 | $48,233 | -12.17% | |
| 2013-03-06 | Sale | Akirov Alfred | director | 4,700 0.0051% | $5.69 | $26,737 | -11.71% | |
| 2012-05-02 | Sale | Shaaltiel Yoseph | Executive VP, R&D | 300,000 0.3334% | $7.13 | $2.14M | -20.83% |
| Camber Capital Management LLC | 10 percent owner | 10775000 13.5352% | $15.62M | 1 | 1 | <0.0001% |
| Bronfeld Zeev | 10066319 12.645% | $14.6M | 0 | 1 | ||
| Bio-Cell Ltd | 10 percent owner | 10066319 12.645% | $14.6M | 0 | 1 | |
| FROST PHILLIP MD ET AL | 10 percent owner | 7610167 9.5597% | $11.03M | 2 | 25 | +14.01% |
| Akirov Alfred | director | 4915383 6.1746% | $7.13M | 0 | 7 | |
| Dexcel Pharma Technologies Ltd. | 10 percent owner | 3637314 4.5691% | $5.27M | 0 | 2 | |
| Hurvitz Eli | director | 1514480 1.9024% | $2.2M | 0 | 1 | |
| Shaaltiel Yoseph | Executive VP, R&D | 463754 0.5826% | $672,443.30 | 4 | 16 | <0.0001% |
| Schwartz Aharon | director | 174000 0.2186% | $252,300.00 | 2 | 0 | +42% |
| Bashan Dror | PRESIDENT AND CEO | 132516 0.1665% | $192,148.20 | 2 | 0 | <0.0001% |
| Manor Moshe | President & CEO | 50000 0.0628% | $72,500.00 | 1 | 0 | <0.0001% |
| Maimon Yossi | Vice President & CFO | 10000 0.0126% | $14,500.00 | 1 | 13 | <0.0001% |
| Bar-Shalev Amos | director | 1680 0.0021% | $2,436.00 | 1 | 0 | <0.0001% |
| Aviezer David | President & CEO | 0 0% | $0 | 0 | 11 | |
| Almon Einat Brill | SVP, Product Development | 0 0% | $0 | 0 | 12 |
$5,102,291 | 146 | 5.58% | $110.81M | |
$30,470,407 | 140 | 20.39% | $106.76M | |
$49,091,668 | 110 | 13.11% | $104.01M | |
$48,218,096 | 42 | 0.89% | $125.2M | |
$909,129 | 37 | 42.19% | $110.75M | |
$6,915,275 | 21 | -32.61% | $118.83M | |
$26,678,853 | 21 | -5.95% | $102.99M | |
$33,027,560 | 17 | -10.02% | $105.49M | |
Protalix BioTherapeutics, Inc. (PLX) | $4,701,608 | 14 | -4.34% | $115.43M |
$145,194 | 11 | -27.37% | $108.75M | |
$1,073,250 | 10 | 19.46% | $125.66M | |
$9,999,920 | 10 | -40.03% | $128.37M | |
$478,647 | 7 | 69.41% | $124.34M | |
$68,692,148 | 6 | -39.10% | $124.17M | |
$4,745,999 | 5 | -4.91% | $118.18M | |
$59,900 | 4 | -5.37% | $118.39M | |
$762,555 | 4 | -34.52% | $111.9M | |
$30,149,552 | 3 | -66.74% | $103.29M | |
$19,175,155 | 2 | 40.00% | $122.87M |
| Increased Positions | 41 | +87.23% | 4M | +93.95% |
| Decreased Positions | 18 | -38.3% | 614,781 | -13.55% |
| New Positions | 22 | New | 2M | New |
| Sold Out Positions | 7 | Sold Out | 144,940 | Sold Out |
| Total Postitions | 70 | +48.94% | 8M | +80.4% |
| Renaissance Technologies Llc | $3,354.00 | 1.42% | 1.12M | +162,100 | +16.96% | 2024-12-31 |
| Northern Trust Corp | $2,195.00 | 0.93% | 731,742 | +679,451 | +1,299.37% | 2024-12-31 |
| Millennium Management Llc | $1,164.00 | 0.49% | 387,921 | +14,164 | +3.79% | 2024-12-31 |
| Stratos Wealth Partners, Ltd. | $1,039.00 | 0.44% | 346,400 | +76,400 | +28.3% | 2025-03-31 |
| Gsa Capital Partners Llp | $917.00 | 0.39% | 305,749 | -129,464 | -29.75% | 2024-12-31 |
| Blackrock, Inc. | $764.00 | 0.32% | 254,535 | +29,878 | +13.3% | 2025-03-31 |
| Bridgeway Capital Management, Llc | $544.00 | 0.23% | 181,400 | -2,390 | -1.3% | 2024-12-31 |
| Morgan Stanley | $511.00 | 0.22% | 170,216 | +127,158 | +295.32% | 2024-12-31 |
| Citadel Advisors Llc | $437.00 | 0.19% | 145,787 | +54,129 | +59.05% | 2024-12-31 |
| Jane Street Group, Llc | $341.00 | 0.14% | 113,616 | +67,664 | +147.25% | 2024-12-31 |